Self-Injection, Trans-Urethral and Topical Therapy in Erectile Dysfunction

Standard Practice in Sexual Medicine

Volumn , Issue , 2008, Pages 94-108

  Porst, Hartmut ^a   Adaikan, Ganesan ^b  

^a Neuer Jungfernstieg 6a   (Germany)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Clinical management; Diagnostic investigations; Erectile dysfunction; Topical therapy; Vasculogenic impotence

Indexed keywords

EID: 84889268929     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470755235.ch8     Document Type: Chapter

References (94)

1. Virag R. Intracavernous injection of papaverine for erectile failure Lancet 1982;2(8304):938
2. Virag R, Frydman D, Legman M, Virag H. Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure. Angiology 1984;35(2):79-87.
3. Karim SMM, Hillier K. Physiological roles and pharmacological actions of prostaglandins in relation to human reproduction. In Karim SMM, ed. Prostaglandins and Reproduction. Lancaster: MTP Press Ltd, 1975, pp. 23-75.
4. Adaikan PG. Pharmacology of human penis. MSc Thesis. University of Singapore 1979, pp. 1-213.
5. Adaikan PG, Karim SM, Kottegoda SR, Ratnam SS. Cholinoreceptors in the corpus cavernosum muscle of the human penis. J Auton Pharmacol 1983;3(2):107-11.
6. Hedlund H, Andersson KE. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 1985;134(6):1245-1250.
7. Adaikan PG, Kottegoda SR, Ratnam SS. A possible role for prostaglandin E1 in human penile erection. In: Abstracts of the 2nd World Meeting on Impotence, Prague, 1986;2:6.
8. Ishii N, Watanabe H, Irisawa C, Kikuchi Y, Kawamura S, Suzuki K, Chiba R, Tokiwa M, Shirai M. Studies on male sexual impotence. Report 18. Therapeutic trial with prostaglandin E1 for organic impotence. Nippon Hinyokika Gakkai Zasshi 1986;77(6):954-962.
9. Adaikan PG. Investigations and management of male impotence. In Proceedings of the XXI Malaysia-Singapore Congress of Medicine. Academy of Medicine, Malaysia, 1987, pp. 103-109.
10. Virag R, Adaikan PG. Effects of prostaglandin E1 on penile erection and erectile failure. J Urol 1987;139:1010.
11. Lin JS, Lin YM, Jou YC, Cheng JT. Role of cyclic adenosine monophosphate in prostaglandin E1-induced penile erection in rabbits. Eur Urol 1995; 28(3):259-265.
12. Lee SW, Wang HZ, Zhao W, Ney P, Brink PR, Christ GJ. Prostaglandin E1 activates the large-conductance KCa channel in human corporal smooth muscle cells. Int J Impot Res 1999;11(4):189-199.
13. Molderings GJ, van Ahlen H, Gothert M. Modulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors. Int J Impot Res 1992;4:19-25.
14. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secre tion and effects in the corpus cavernosum. J Urol 1997;157(5):1920-1925.
15. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996;155(3):802-815.
16. Roy AC, Adaikan PG, Sen DK, Ratnam SS. Prostaglandin 15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection. Br J Urol 1989;64(2):180-182.
17. Moreland RB, Traish A, McMillin MA, Smith B, Goldstein I, Saenz de Tejada I. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol 1995;153:826-834.
18. Adaikan PG, LC Lau, Singh G, Susheela K, Vasatha Kumari K, Ratnam SS. Long-term intracavernous injection of papaverine and saline are detrimental to the primate cavernosum as compared to PGE1. Int J Impot Res 1990;2(2):237-238.
19. Moemen MN, Hamed HA, Kamel II, Shamloul RM, Ghanem HM. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances. Int J Impot Res 2004;16(2):143-145.
20. Wespes E, Sattar AA, Noel JC, Schulman CC. Does prostaglandin E1 therapy modify the intracavernous musculature? J Urol 2000;163(2):464-466.
21. Brock G, Tu LM, Linet OI. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Urology 2001;57:536-541.
22. Marshall GA, Breza J, Lue TF. Improved hemodynamic response after long-term intracavernous injection for impotence. Urology 1994;43(6):844-848.
23. Thiounn N, Flam T, Zerbib M, Debre B. Does prostaglandin El (PGE1) help restoration of spontaneous erections? J Urol (Paris) 1993;99(3):136-138.
24. Schultheiss A, Pilatz A, Gabouev N, Schlote J, Wefer H, Mertsching M, Sohn U, Jonas C. Stief. Cytotoxicity of different intracavernous vasoactive drugs on cultured endothelial cells of human corpus cavernosum penis. Urology 2004;64(3):598-602.
25. Adaikan PG, Ratnam SS. Pharmacological consideration of intracavernous drug injection in the treatment of impotence. Acta Urol Belg 1988;56(2):149-153.
26. Kirkeby HJ, Forman A, Andersson KE. Comparison of the papaverine effects on isolated human penile circumflex veins and corpus cavernosum. Int J Impot Res 1990;2:49-54.
27. Iguchi M, Nakajima T, Hisada T, Sugimoto T, Kurachi Y. On the mechanism of papaverine inhibition of the voltage-dependent Ca++ current in isolated smooth muscle cells from the guinea pig trachea. J Pharmacol Exp Ther 1992;263(1):194-200.
28. van Ahlen H, Piechota H-J, Hermanns M, Kruger E. Metabolic changes in the human corpus cavernosum under vasoactive substances. Int J Imp Res 1990;2(suppl 2):244.
29. Stackl W, Loupal G, Holzmann A. Intracavernous injection of vasoactive drugs in the rabbit. Urol Res 1988;16:455-458.
30. Gupta S, Gallant C, Traish A, et al. Relaxation of corpus cavernosum smooth muscle by phentolamine via a non-adrenergic mechanism. Int J Impotence Res 1998;10:Suppl 3, S27.
31. Traish AM, Gupta S, Gallant C, et al. Phentolamine mesylate relaxes penile corpus cavernosum by adrenergic and non-adrenergic mechanisms. Int J Impotence Res 1998;10:215-223.
32. Juenemann KP, Lue TF, Fournier JR, GR, et al. Hemodynamics of papaverine- and phentolamine-induced penile erection. J Urol 1986;136:158-161.
33. Blum MD, Bahnson RR, Porter TN, et al. Effect of local alpha-adrenergic blockade on human penile erection. J Urol 1985;134:479-481.
34. Zorgniotti AW, Lefleur RS. Autoinjection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985;133:39-41.
35. Buvat J, Lemaire A, Buvat-Herbaut M, et al. Safety of intracavernous injections using an alpha-blocking agent. J Urol 1989;141:1364-1367.
36. Buvat J, Costa P, Morlier D, et al. Double-blind multicenter study comparing alprostadil alpha cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol 1998;159:116-119.
37. Polak JM, Gu J, Mina S, Bloom SR. Vipergic nerves in the penis. Lancet 1981;2(8240):217-219.
38. Ehmke H, Juenemann KP, Mayer B, Kummer W. Nitric oxide synthase and vasoactive intestinal polypeptide colocalization in neurons innervating the human penile circulation. Int J Impot Res 1995;7(3): 147-156.
39. Hedlund P, Ny L, Alm P, Andersson KE. Cholinergic nerves in human corpus cavernosum and spongiosum contain nitric oxide synthase and heme oxygenase. J Urol 2000;164(3 Pt 1):868-875.
40. Kirkeby HJ, Fahrenkrug J, Holmquist F, Ottesen B. Vasoactive intestinal polypeptide (VIP) and peptide histidine methionine (PHM) in human penile corpus cavernosum tissue and circumflex veins: localization and in vitro effects. Eur J Clin Invest 1992;22(1):24-30.
41. Hedlund P, Alm P, Ekstrom P, Fahrenkrug J, Hannibal J, Hedlund H, Larsson B, Andersson KE. Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum. Br J Pharmacol 1995;116(4):2258-2266.
42. Adaikan PG, Kottegoda SR, Ratnam SS. Is vasoactive intestinal polypeptide the principal transmitter involved in human penile erection? J Urol 1986;135(3): 638-640.
43. Roy JB, Petrone RL, Said SI. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection. J Urol 1990;143(2):302-304.
44. Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Machtens SA, Kuczyk MA, Jonas U. Systemic and cavernous plasma levels of vasoactive intestinal polypeptide during sexual arousal in healthy males. World J Urol 2002;20(1):59-63.
45. Cormio L, Gesualdo L, Maiorano E, Bettocchi C, Palumbo F, Traficante A, Schenaand FP, Selvaggi FP. Vasoactive intestinal polypeptide (VIP) is not an androgen- dependent neuromediator of penile erection. Int J Impot Res 2005;17:23-26.
46. Miller MA, Morgan RJ, Thompson CS, Mikhailidis DP, Jeremy JY. Effects of papaverine and vasointestinal polypeptide on penile and vascular cAMP and cGMP in control and diabetic animals: an in vitro study. Int J Impot Res 1995;7(2):91-100.
47. Kim NN, Goldstein I, Moreland RB, Traish AM. Alpha-adrenergic receptor blockade by phentolamine increases the efficacy of vasodilators in penile corpus cavernosum. Int J Impot Res 2000;12(Suppl 1):S26-36.
48. Goldstein I, Borges FD, Fitch WP, et al. Rescuing the failed papaverine/phentolamine erection: A proposed synergistic action of papaverine, phentolamine and prostaglandin E1. J Urol 1990;143:4 Suppl, 304A.
49. Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991;146(6):1564-1565.
50. Govier FE, McClure RD, Weissman RM, et al. Experience with triple-drug therapy in a pharmacological erection program. J Urol 1993;150:1822-1824.
51. Israilov S, Niv E, Livne PM, et al. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. Int J Impot Res 2002;14(1):38-43.
52. Marshall GA, Breza J, Lue TF. Improved hemodynamic response after long-term intracavernous injection for impotence. Urology 1994;43(6):844-848.
53. Shenfeld O, Hanani J, Shalhav A, et al. Papaverinephentolamine and prostaglandin E1 versus papaverine- phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J Urol 1995;154(3):1017-1019.
54. Mulhall JP, Jahoda AE, Cairney M, et al. The causes of patient dropout from penile self-injection therapy for impotence. J Urol 1999;162(4):1291-1294.
55. Montorsi F, Salonia A, Zanoni M, et al. Current status of local penile therapy. Int J Impot Res 2002;14(Suppl): S70-81.
56. Kulaksizoglu H, Hakim LS, Nehra A, et al. Comparison of alprostadil sterile powder (CaverjectTM) with trimix Nomogram and patient satisfaction. J Urol 1997;157: No. 4 Suppl, 180.
57. Gerstenberg TC, Metz P, Ottesen B, et al. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 1 1992;47:1277-1279.
58. Hackett G, and the UK-group of investigators. A 12-month multicenter placebo-controlled study of InvicorpTM in the treatment of non-psychogenic erectile dysfunction. Int J Impotence Res 1998;10:Suppl. 3, S21.
59. Sandhu D, Curless E, Dean J, et al. A double blind, placebo-controlled study of intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel autoinjector for the treatment of nonpsychogenic erectile dysfunction. Int J Impotence Res 1999;11:91-97.
60. Porst, H. Manual der Impotenz, Uni-Med Verlag, 2000, Bremen, Germany.
61. McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injecition nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 1999;162:1992-1998.
62. Gutierrez P, Hernadez P, Mas M. Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. Int J Impot Res 2005;17:354-358.
63. Porst H, Buvat J, Meuleman E, et al. Intracavernous alprostadil alfadex-an effective and well tolerated treatment for erectile dysfunction. Results of a longterm European study. Int J Impotence Res 1998;10: 225-231.
64. Linet OJ. Long-term safety of CaverjectTM (alprostadil S.PO, PGE) in erectile dysfunction (ED). Int J Impotence Res 1998;10:Suppl.3, S37.
65. Chew KK, Stuckey BGA. Clinical course of penile fibrosis in intracavernosal prostaglandin E1 injection therapy: a follow-up of 44 patients. Int J Impotence Res 2003;15:94-98.
66. Hashmat AJ, Abrahams J, Fani K, et al. A lethal complication of papaverine-induced priapism. J Urol 1991; 145:146-147.
67. Limoge JP, Olins E, Henderson D, et al. Minimally invasive therapies in the treatment of erectile dysfuction in anticoagulated cases: A study of satisfaction and safety. J Urol 1996;155:1277-1279.
68. Mansi MF, Ackhudair WK, Huraib S. Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. J Urol 1998;159:1927-1930.
69. Plekhanov AY, Zhivovo AV, Goryachew LA. Comparative complications rate after alprostadil intracavernous pharmacotherapy for erectile dysfunction in diabetes mellitus vs. non-diabetic patients. Int J Impotence Res 1998;10:Suppl 3, S50
70. Padma-Nathan H, Keller T, Poppiti R, et al. Hemodynamic effects of intraurethral alprostadil: The Medicated Urethral System for Erection (MUSE®). J Urol 1994;151:No. 5, 345.
71. Ghazi SA, Al Meligy A. Transurethral alprostadil and the prostaglandin E1 intra corporal injection in treatment of erectile dysfunction: A comparative study. Int J Impotence Res 1998;10:Suppl.3, S13.
72. Werthman P, Rajfer J. MUSE-therapy: preliminary clinical observations. Urology 1997;50:809-811.
73. Porst H. Transurethral alprostadil with MUSETM (Medicated Urethral System for Erection) vs. intracavernous alprostadil-a comparative study in 103 patients with erectile dysfunction. Int J Impotence Res 1997;9:187-192.
74. Shabsigh R, Padma-Nathan H, Gittelman M, et al. and the EDEX®/VIRIDAL® Study Group: Comparative results of efficacy and safety of intracavernous alprostadil alfadex (EDEX®/VIRIDAL®) and intraurethral alprostadil (MUSE®) plus ACTIS®. Int J Impotence Res 1998;10:Suppl., S51.
75. Shabsigh R, Padma-Nathan H, Gitteman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology 2000;55: 109-113.
76. Flynn TN, Guest JF. Intracorporeal and transurethral application of alprostadil: A review of the literature. Int J Impotence Res 1998;10:Suppl.3, S47.
77. Mydlo JH, Volpe, MA, Maccia RJ. Inital results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 2000;38:30-34.
78. Nehra A, Hakim L, Barrett DM, et al. Effectiveness of combination therapy of MUSE and Viagra in the salvage of erectile dysfunction patients desiring noninvasive therapy: 18-month follow-up. Int J Impotence Res. 12, 9th World Meeting on Impotence Research, Perth, 2000;p.23:P23
79. See RJ, Williams J, Sparkuhl A, et al. Lyophilized Liposomal Prostaglandin E1 released by a dilute detergent for intrameatal delivery to treat erectile failure. J Urol 1997;157: No.4, Suppl.201
80. Engelhardt PF, Plas E, Hübner WA, et al. Comparison of intraurethral liposomal and intracavernosal prostaglandin E1 in the management of erectile dysfunction. Br J Urol 1998;81:441-444.
81. Schmidt AC. Prostaglandin E2 gel: an alternative treatment for erectile dysfunction. Int J Impotence Res 1994;6:Suppl.1, A43.
82. Wolfson B, Pickett S, Scott NE, et al. Intraurethral prostaglandin E2 cream: a possible alternative treatment for erectile dysfunction. Urology 1993;42:73-75.
83. Maibach HI, Feldman RJ, Milby TH, Serat WF. Regional variation in percutaneous penetration in man. Arch Environ Health 1971;23(3):208-211.
84. McVary KT, Polepalle S, Riggi S, Pelham RW. Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction. J Urol 1999;162(3 Pt 1):726-730.
85. Goldstein I, Payton TR, Schechter PJ. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology 2001;57(2):301-305.
86. Radomski SB, Herschorn S, Rangaswamy S. Topical minoxidil in the treatment of male erectile dysfunction. J Urol 1994;151(5):1225-1226.
87. Chancellor MB, Rivas DA, Panzer DE, Freedman MK, Staas WE Jr. Prospective comparison of topical minoxidil to vacuum constriction device and intracorporeal papaverine injection in treatment of erectile dysfunction due to spinal cord injury. Urology 1994;43(3): 365-369.
88. Beretta G, Saltarelli O, Marzotto M, Zanollo A, Re B. Transcutaneous minoxidil in the treatment of erectile dysfunctions in spinal cord injured men. Acta Eur Fertil 1993;24(1):27-30.
89. Johnson GA, Barsuhn KJ, McCall JM. Minoxidil sulfate, a metabolite of minoxidil. Drug Metab Dispos 1983; 11(5): 507-508.
90. Cavallini G. Minoxidil versus nitroglycerine: a prospective, double-blind, controlled trial in transcutaneous therapy for organic impotence. Int J Impot Res 1994;6(4):205-212.
91. Nunez BD, Anderson DC Jr. Nitroglycerin ointment in the treatment of impotence. J Urol 1993;150(4): 1241-1243.
92. Owen JA, Saunders F, Harris C, Fenemore J, Reid K, Surridge D, Condra M, Morales A. Topical nitroglycerin: a potential treatment for impotence. J Urol 1989;141(3):546-548.
93. Kim ED, el-Rashidy R, McVary KT. Papaverine topical gel for treatment of erectile dysfunction. J Urol 1995;153(2):361-365.
94. Chiang HS, Kao YH, Sheu MT. Papaverine and prostaglandin E1 gel applications for impotence. Ann Acad Med Singapore 1995;24(5):767-769.